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ABSTRACT
Introduction: One of the recent advances in assessing outcomes of medical
care is the inclusion of the patient perspective. The term patient-reported
outcome (PRO) is used to reﬂect the patient perceptions of disease and its
consequences as well as of treatment and health-care provision. The devel-
opment of PRO measures has advanced rapidly, and implementation in
clinical research and practice is now underway. From an evaluation per-
spective, recommendations for the choice of PRO measures and an
appraisal of the potential beneﬁts of PRO data collection within speciﬁc
health conditions are needed.
Methods: Hemophilia is a rare and clinically well-deﬁned health condi-
tion with established and cost-intensive treatment strategies, in which
PRO assessment is increasingly recognized as important. For this reason,
measurement of PROs in hemophilia focusing on health-related quality
of life (HRQoL) and patient preferences were reviewed to identify
appropriate measures, to make recommendations for their choice, and to
critically examine their impact in international hemophilia research and
practice.
Results: Using literature searches and expert discussion strategies, generic
and targeted measures for HRQoL and patient preferences in adults and
children with hemophilia were screened, and 20 were reviewed on the
basis of their psychometric properties and international availability. Only
a few of the 20 measures have been used in clinical settings or research
related to persons with hemophilia.
Conclusion: Consequently, an increased use of these measures is recom-
mended to understand patient views on disease and treatment and to judge
the impact of PROs for improvements in health care.
Keywords: assessment, hemophilia, patient-reported outcomes, patient
preferences, quality of life.
Background
Recently, there has been a growing interest in including patient-
reported outcomes (PROs) as secondary or primary end points in
medical research. PROs are efﬁcacy measures for evaluating the
beneﬁts of new and existing treatments. A PRO can be deﬁned as
any report coming directly from patients, without interpretation
by physicians or persons, about how they function or feel in
relation to a health condition and its treatment [1]. PROs
include, but are not limited to, measures of quality of life, health
status, treatment preferences, and patient satisfaction. They aim
at capturing disease and treatment from the patient’s perspective
to better assess the value of the treatment received and to rec-
ommend strategies for improved care. This is especially impor-
tant in chronic health conditions with high demands on care,
often involving lifelong therapies, as is the case in hemophilia.
Hemophilia is a rare congenital disorder characterized by
spontaneous and post-traumatic bleeding events due to low levels
of blood-clotting factors. Hemorrhages are particularly frequent
in joints and cause progressive destruction of articular structures,
leading to impairment of joint function and chronic pain. Intrac-
erebral and gastrointestinal hemorrhages are infrequent, but life-
threatening. The major goal in treating patients with hemophilia
is to reduce the frequency of bleeds, and consequently, mortality
and joint damage to prevent future disability.
Treatment is based on replacement of the missing clotting
factor when a bleed occurs (on-demand treatment) or regularly
and continuously (prophylactic treatment). The cost of therapy is
extremely high mainly because of the costs of clotting factor
concentrates [2]. In developed countries, it is estimated to be
about €60,000 per patient year on average, but the costs can
increase to €220,000 per patient year in patients with treatment
complications such as the development of clotting factor-
inhibiting antibodies. These costs are distributed differently
between patients and payers in different countries. Dose, fre-
quency, and type of replacement therapy in hemophilia vary
depending not only on severity of the disease, patient age, lif-
estyle, and preferences and treatment schemes, but also on avail-
ability of factor concentrates and the reimbursement and the
distribution system in the country in which it is being given.
Reimbursement for prophylactic therapy also varies along a
continuum of full to no reimbursement. On one end of the
continuum, countries such as Germany and Canada provide
reimbursement for prophylactic care for all hemophilic patients.
In the middle are countries such as the United States where
reimbursement is variable depending on individual insurer
restrictions. On the other end of the continuum are countries
such as India where no prophylactic care is provided for patients
with hemophilia. Translating quality of life gains from prophy-
laxis into economic analyses is imperative for decision-makers
who must decide whether or not to reimburse prophylactic treat-
ment with factor concentrate for patients with hemophilia.
Bleeding frequency and joint damage have been the key
outcome measures to evaluate treatment strategies in clinical
studies and in routine practice. Assessment of PROs is increasingly
considered necessary to understand which treatment strategy is
clinicallymost effective and ﬁts the patient’s needs best [3]. Among
the different PRO approaches, this current article focuses on two:
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health-related quality of life (HRQoL) and patient preference
measures (PPMs) [4]. In the subsequent review of measures,
careful evaluation of conceptual background, methodological
quality, clinical practicability, and international availability was
carried out and information on the use of thesemeasures in clinical
research and practice was gathered.
A Brief Overview of HRQoL Assessment
Conceptually, HRQoL has been deﬁned as reﬂecting a person’s
valuation of goals, expectations, and aspirations with regard to
different areas of life. More speciﬁcally, HRQoL has been viewed
as the subjective perception of well-being and function in different
life domains, namely concerning physical, social, emotional,
mental, and everyday life or role performance [5]. The inclusion of
the term HRQoL in medical research reﬂects the need to address
patients’ perspectives of their health conditions and treatments.
Because the focus on health constitutes a more speciﬁc aspect of
quality of life, the term HRQoL has been coined to describe
patient-perceived health status and treatment experience [6].
HRQoL instruments differ in aspects such as scope (generic
or chronic generic vs. targeted), respondents (adults vs. children
or adolescents), form of administration (self-completed, ques-
tionnaire, or computer administration vs. interview), mode of
response (self-report vs. proxy report or observation), purpose
of assessment (descriptive, evaluative, or predictive), and method
of development (psychometric primarily based on psychological
test theory vs. clinimetric primarily based on clinical epide-
miology principles to integrate the perspectives of patients and
clinicians) [7,8]. In psychometric and clinimetric paradigms, reli-
ability refers to the precision of a measure (e.g., internal consis-
tency, test–retest) and validity refers to the correct representation
of the concept to be measured in the questionnaire (e.g., face,
criterion, construct validity). Within either construct or criterion
validity, discriminant validity denotes the ability of the measure
to distinguish between different clinical subgroups, and conver-
gent validity denotes the correspondence of the measure with
other instruments measuring similar concepts.
In general, instruments also differ regarding their purpose of
use, ranging from diagnosis of the individual patient in a speciﬁc
clinical context over outcome assessment in prospective observa-
tional studies or controlled clinical trials to epidemiological
studies [9,10].
Generic measures are designed to be applicable to persons
with a variety of health conditions, including the general popu-
lation where most subjects have no disease or deﬁned health
condition. Targeted—or disease-speciﬁc measures—are devel-
oped speciﬁcally for a deﬁned clinical population, and hence
focus on the most relevant health issues for that group. Both
types of measures have been developed for adults and for
children/adolescents.
The availability of measures for use in different cultural
contexts is also of importance. Steps in the construction of an
internationally usable instrument involve item development,
translation, psychometric testing (e.g., examination of reliability,
validity, and responsiveness), and norming (obtaining reference
data for the questionnaire from large nonclinical or clinical
populations) in the respective country. Guidelines on how to
conduct these steps have been published [11,12].
A Brief Overview of PPM
Patient preferences (also referred to as utilities) can be character-
ized as numeric measures that represent the value placed on a
particular health state [13]. The number reﬂects how much risk
that individual would be willing to take in exchange for a speciﬁc
improvement in this health state and provides standardized
metrics to compare different outcomes across various diseases.
PPMs may differ depending on whose values are applied—those
of the individual vs. those of society. Preferences for a health state
may be elicited either directly or indirectly.
Direct measurement, a theoretically based measure involv-
ing choice, requires respondents to value a prespeciﬁed health
state [14], using one of three current approaches to assess pref-
erences or utilities directly: standard gamble (SG), time-tradeoff
(TTO), and visual analogue scale (VAS). These three methods
most often yield different preference scores [15]. With these
measures, a patient has to decide between a theoretical lifetime
that he/she would be willing to give in exchange for a beneﬁcial
treatment (TTO), or which risk a patient would take for which
probability of being cured (SG) or how desirable a health
outcome is (VAS).
Indirect measurement involves using a health status instru-
ment where the preferences have been assigned independent
of the study, preferably by community-based judges. These
preference-based measures with preassigned weights (preference
scores) theoretically yield scores that are comparable with mea-
sures elicited directly, and the differences in methods are in the
deﬁnition of health states [16].
Recently, patient preferences have been derived from existing
quality of life scales by using items and response categories to
construct health state scenarios that patients are then asked to
rate in terms of preferences. If these states are then rated a priori
by community-based judges, it is possible to assign utilities as
well [17].
This article reviews the PRO assessment in the ﬁeld of hemo-
philia with speciﬁc attention to different age groups (childhood,
adolescence, and adulthood). The purpose is to identify valid and
reliable HRQoL and PPMs measures for use in prophylaxis
research, to critically examine the current use of these measures
in clinical studies, and to evaluate the impact of PRO assessment
in hemophilia.
Methods
A literature review on HRQoL or PPM was performed using the
MEDLINE System with the aim to identify disease-speciﬁc or
targeted measures for children and adults in the hemophilia ﬁeld
and to examine which of these measures in fact had been used in
published hemophilia studies. An important aspect for such mea-
sures is that they reﬂect patient perceptions from the start of
instrument development and that they provide information
whether and how patient input was used to develop key domains
and items. For the literature analysis, a PubMed search was
conducted using the keywords “haemophilia” with “quality of
life,” and with “patient preferences” or “utilities” without limi-
tation in publication date or language. Criteria for the inspection
of a publication were:
1. description of approaches to measurement as well as infor-
mation on the PRO instrument creation ranging from the
generation of items to the ﬁnalization of the instrument;
2. description of an instrument with data about the method-
ological quality of the measure in terms of reliability, valid-
ity, and responsiveness;
3. information on the availability of language versions other
than the original language, with measures preferably not
only translated but also validated in these languages; and
4. the presence of empirical data reported in outcome studies
about these measures from the literature including their
actual use in research and practice.
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The keywords (text words) “haemophilia” or “hemophilia”
combined with “quality of life” resulted in 210 publications,
combined with “patient preferences,” 30 articles were found,
and when combined with “utilities,” 7 articles remained. In the
second stage, a more detailed search was conducted; articles were
inspected in terms of their design and psychometric characteris-
tics. In addition, reviews of HRQoL and PPMs published within
the area of hemophilia were included in the results presented here
[18–24]. The current review attempts to add to these existing
reviews by including the most recent information on instrument
development and by conjointly addressing patient preference and
quality of life measures.
Using this strategy, a total of 20 quality of life measures were
inspected: ﬁve generic measures for adults, six generic measures
for children, ﬁve targeted measures for adults, and four targeted
measures for children. For patient preference assessment, four
generic instruments for adults, two generic instruments for chil-
dren, one targeted instrument for adults, and no targeted instru-
ment for children were found. These measures were examined for
the report of psychometric criteria (reliability, validity, respon-
siveness) and for available translations or validation in other
than the original language. To examine targeted measures, the
criteria speciﬁed for evaluating PRO instruments were derived
from the US Food and Drug Administration (FDA) PRO Draft
Guidance [25]; these include information on the conceptual
framework and intended application, development of the instru-
ment, psychometric properties, and the origin of the instruments.
The results of this review were then screened for the applica-
tion of measures in actual studies. A second PubMed search was
carried out in which the instruments’ names, as one keyword,
was connected with the term haemophilia or hemophilia. Both
search strategies were performed as a basis for expert discussions
within the HRQoL expert working group of the International
Prophylaxis Study Group (IPSG), a subgroup of which met
several times over a period of 4 years to arrive at a consensus
about HRQoL and PPM assessment in hemophilia. The goal of
the subgroup was to arrive at guidelines for clinicians and
researchers in selecting relevant HRQoL measures and PPMs,
and in implementing PRO measures in area of hemophilia.
Results: Quality of Life
Quality of Life Measures for Adults and for Children
Adult generic measures. A number of generic measures to assess
HRQoL in adults have been developed over the past 30 years.
The four most frequently used and internationally available mea-
sures were the Sickness Impact Proﬁle (SIP) [26], Nottingham
Health Proﬁle (NHP) [27], the World Health Organization
Quality of Life Assessment (WHOQOL) [28,29], and the SF-36
Health Survey [30,31]. In general, these instruments’ psychomet-
ric properties have been examined in a wide variety of studies.
The SIP and NHP were the ﬁrst measures developed to capture
the subjective representation of health—they were primarily ori-
ented toward identifying major impairments in self-reported
health, although newer measures such as the WHOQOL-100
and its short version, the WHOQOL-BREF [32], as well as the
SF-36 Health Survey and its abbreviated version SF-12 [33],
represent the positive and negative spectrum of functioning and
well-being. Because of their generic nature and their known
measurement properties, they are principally applicable for
HRQoL assessment across health conditions including hemo-
philia. Information on these measures, as shown in Table 1,
indicates good psychometric properties, but there are differences
in item number and in the existence of short versions. With the
exception of the internationally derived WHOQOL, the instru-
ments have been developed originally in English. In addition,
these instruments have been translated in a variety of languages
and many have been validated in different countries. As an
example, over 80 language versions exist for the SF-36, which
has undergone validation and norming in many countries
(http://www.qualitymetric.com).
Nevertheless, only a few of the generic measures have been
included in hemophilia studies (SF-36, SF-12, SIP, and the
Quality of Well-Being Index (QWB)). As already reported in
earlier reviews, the most frequently included measure is the
SF-36/SF-12 Health Survey. An (up-to-date) PubMed review
(June 2007) conﬁrmed this: 13 hemophilia articles were cited for
the SF-36 [34,35] and 2 articles were cited for the SF-12. In
comparison, the SIP has been cited in only one hemophilia study
[36], and the NHP and the WHOQOL have not been used in
adult patients with hemophilia according to the literature. Two
other generic PRO instruments have been included in two hemo-
philia studies, namely the QWB and the Manchester Minneapolis
QoL Index [37,38].
In addition, targeted measures for chronic diseases with con-
sequences for joint function and movement have been developed
such the Western Ontario and McMaster Universities Osteoar-
thritis Index (WOMAC) [39,40], and the Arthritis Impact Mea-
surement Scales (AIMS-2 [41]). The AIMS-2 has been cited ﬁve
times, and is the most prominent chronic generic measure used in
the hemophilia ﬁeld. By contrast, the WOMAC has been cited
once [42] in this ﬁeld. An older measure, the Stanford Health
Assessment Questionnaire [43] has recently been recommended
of functional impairment because of arthropathy [44]. Albeit
developed for other chronic diseases, these targeted measures
deserve further psychometric testing in the hemophilia patient
population before they can be used in hemophilia to assess the
level of speciﬁc functional impairments.
Child generic measures. In terms of children’s quality of life
assessment, efforts have recently been directed toward develop-
ing and testing scales measuring quality of life from the child’s (as
well as parents’) perspective and in different age groups [45].
Several generic measures such as the Child Health Questionnaire
(CHQ) by Landgraf [46] and the PedsQL by Varni [47] have been
developed in the United States, while other measures such as the
KINDL/KINDL-R questionnaire for child self-report and for
parental proxy report [48,49] and TACQOL [50] have been
developed in Europe. Most recently, two multinationally devel-
oped instruments are available for use: the KIDSCREEN [51,52]
and the DISABKIDS measure [53,54]. Many of these measures
have been developed during the past decade, and have been
designed to be applicable to children’s age and developmental
status. Some of them already include self-report in children from
age 4 on, although for younger children, only parent report is
possible. Differences between age group versions of an instru-
ment relate to the number of items, their formulation, and the
type of domains included. The number of items tends to be low,
and parents’ report paralleling children’s items is frequently
available. Short forms are often developed in a way to make
assessment across a number of items in age groups possible.
The CHQ is available in child and parent forms and has been
extensively and successfully psychometrically tested. This is also
true for the KINDL-R questionnaire, which includes three age
group versions for children 4 to 7, 8 to 11, and 12 to 16. The
TACQOL is again available for older children in parent and
self-report. The PedsQL subdivides four age groups (2–4, 5–7,
8–12, and 13–18) with 23 items, is available in self- and parent-
report in over 20 languages, and is one of the most widely used
810 Bullinger et al.
Ta
bl
e
1
(a
)
G
en
er
ic
Q
oL
m
ea
su
re
s
fo
r
ad
ul
ts
;(
b)
ge
ne
ri
c
Q
oL
m
ea
su
re
s
fo
r
ch
ild
re
n
In
st
ru
m
en
t
ch
ar
ac
te
ri
st
ic
s
M
ea
su
re
m
en
t
pr
op
er
tie
s
(a
)
In
st
ru
m
en
t
A
ut
ho
r
N
o.
of
D
om
ai
ns
N
o.
of
ite
m
s
O
ri
gi
na
lL
an
gu
ag
e
R
el
ia
bi
lit
y
Va
lid
ity
G
en
er
ic
SI
P
Be
rg
ne
r
et
al
.,
19
81
[2
6]
12
13
6
En
gl
is
h
(U
S)
r=
0.
92
a
=
0.
96
C
ri
te
ri
o
n:
co
nc
ur
re
nt
C
o
ns
tr
uc
t:
co
nv
er
ge
nt
di
sc
ri
m
in
an
t
N
H
P
H
un
t
et
al
.,
19
81
[2
7]
6
+
1
38
+
6
En
gl
is
h
(U
K
)
r=
0.
77
–0
.8
5
C
ri
te
ri
o
n:
kn
ow
n
gr
ou
ps
W
H
O
Q
oL
Fa
m
ily
W
H
O
Q
oL
-1
00
Po
w
er
et
al
.,
19
98
,1
99
9
[2
8,
29
,3
2]
6
10
0
In
te
rn
at
io
na
l
a
=
0.
81
(s
um
sc
or
e)
C
o
ns
tr
uc
t:
di
sc
ri
m
in
an
t
W
H
O
Q
oL
-B
R
EF
4
24
a
=
0.
66
–0
.8
4
(s
ub
sc
al
es
)
SF
H
ea
lth
Su
rv
ey
Fa
m
ily
SF
-3
6
H
ea
lth
Su
rv
ey
W
ar
e
et
al
.,
19
92
[3
0]
8
36
En
gl
is
h
(U
S)
*
a
=
0.
68
–0
.9
6
(s
ub
sc
al
es
)
IC
C
=
0.
64
8–
0.
86
8
C
ri
te
ri
o
n:
kn
ow
n
gr
ou
ps
C
o
ns
tr
uc
t:
co
nv
er
ge
nt
di
sc
ri
m
in
an
t
SF
-1
2
H
ea
lth
Su
rv
ey
W
ar
e
et
al
.,
19
96
[3
3]
2
12
a
=
0.
63
–0
.9
1
(s
ub
sc
al
es
)
IC
C
>
0.
80
C
hr
on
ic
ge
ne
ri
c
W
O
M
A
C
Be
lla
m
y
et
al
.,
19
88
[4
0]
24
3
En
gl
is
h
(U
S)
a
=
0.
80
(s
um
sc
or
e)
r=
0.
80
C
o
ns
tr
uc
t:
D
is
cr
im
in
an
t
co
nt
en
t
A
IM
S2
M
ee
na
n
et
al
.,
19
82
[4
1]
12
57
En
gl
is
h
(U
S)
a
=
0.
72
–0
.9
1
r=
0.
78
–0
.9
4
C
ri
te
ri
o
n:
kn
ow
n
gr
ou
ps
(b
)
In
st
ru
m
en
t:
al
li
n
ch
ild
-r
ep
or
t
(C
)
an
d
pa
re
nt
-r
ep
or
t
(P
)
A
ut
ho
r
A
ge
gr
ou
ps
N
o.
of
do
m
ai
ns
N
o.
of
It
em
s
La
ng
ua
ge
R
el
ia
bi
lit
y
Va
lid
ity
G
en
er
ic
K
IN
D
L-
R
R
av
en
s-
Si
eb
er
er
et
al
.1
99
8
[4
9]
4–
7
6
12
G
er
m
an
†
a
=
0.
63
–0
.8
4
(C
)
a
=
0.
62
–0
.8
9
(P
)
C
ri
te
ri
o
n:
kn
ow
n
gr
ou
ps
C
o
ns
tr
uc
t:
co
nv
er
ge
nt
di
sc
ri
m
in
an
t
8–
11
24
12
–1
6
C
H
Q
La
nd
gr
af
et
al
.,
19
97
[4
6]
8–
15
14
87
En
gl
is
h
(U
S)
‡
a
=
0.
63
–0
.9
0
(C
)
a
=
0.
59
–0
.9
4
(P
)
C
o
ns
tr
uc
t:
di
sc
ri
m
in
an
t
TA
C
Q
O
L
T
he
un
is
se
n
et
al
.,
19
98
[5
0]
8–
15
(C
)
5–
15
(P
)
7
56
D
ut
ch
§
a
=
0.
66
–0
.7
9
(C
)
a
=
0.
67
–0
.8
4
(P
)
C
o
ns
tr
uc
t:
di
sc
ri
m
in
an
t
Pe
ds
Q
l
Va
rn
ie
ta
l.,
19
99
[4
7]
5–
7
4
23
En
gl
is
h
(U
S)
||
a
=
0.
88
(C
)
a
=
0.
90
(P
)
IC
C
=
0.
88
(C
)
IC
C
=
0.
90
(P
)
C
o
ns
tr
uc
t:
di
sc
ri
m
in
an
t
8–
12
13
–1
8
K
ID
SC
R
EE
N
R
av
en
s-
Si
eb
er
er
et
al
.,
20
01
[5
1]
8–
18
K
ID
SC
R
EE
N
-5
2
10
52
In
te
rn
at
io
na
l¶
a
=
0.
76
–0
.8
9
C
o
ns
tr
uc
t:
co
nv
er
ge
nt
di
sc
ri
m
in
an
t
8–
18
K
ID
SC
R
EE
N
-2
7
5
27
a
=
0.
79
–0
.8
4
8–
18
K
ID
SC
R
EE
N
-1
0
1
10
a
=
0.
82
C
hr
on
ic
ge
ne
ri
c
D
IS
A
BK
ID
S
Bu
lli
ng
er
et
al
.,
20
02
[5
3]
8–
16
D
C
G
M
-3
7
6
37
In
te
rn
at
io
na
l#
a
=
0.
70
–0
.9
3
(C
)
a
=
0.
77
–0
.9
5
(P
)
C
o
ns
tr
uc
t:
co
nv
er
ge
nt
di
sc
ri
m
in
an
t
8–
16
D
C
G
M
-1
2
3
12
a
=
0.
90
(C
)
a
=
0.
93
(P
)
4–
7
Sm
ile
y
M
ea
su
re
1
6
a
=
0.
69
(C
)
a
=
0.
71
(P
)
*V
al
id
at
ed
La
ng
ua
ge
s
A
fr
ik
aa
ns
,A
ra
bi
c
(Q
at
ar
),
A
ra
bi
c
(S
au
di
A
ra
bi
a)
,A
ra
bi
c
(T
un
is
ia
),
A
rm
en
ia
n
(A
rm
en
ia
),
Bu
lg
ar
ia
n,
C
hi
ne
se
(H
on
g
K
on
g
SA
R
),
C
hi
ne
se
(M
al
ay
si
a)
,C
hi
ne
se
(S
im
pl
iﬁ
ed
),
C
hi
ne
se
(S
in
ga
po
re
),
C
hi
ne
se
(T
ai
w
an
),
C
hi
ne
se
(U
ni
te
d
St
at
es
),
C
ro
at
ia
n,
C
ze
ch
,D
an
is
h,
D
ut
ch
(B
el
gi
um
),
D
ut
ch
(N
et
he
rl
an
ds
),
En
gl
is
h
(A
us
tr
al
ia
),
En
gl
is
h
(C
an
ad
a)
,E
ng
lis
h
(G
re
at
Br
ita
in
),
En
gl
is
h
(H
on
g
K
on
g)
,E
ng
lis
h
(M
al
ay
si
a)
,E
ng
lis
h
(N
ew
Z
ea
la
nd
),
En
gl
is
h
(P
hi
lip
pi
ne
s)
,E
ng
lis
h
(S
in
ga
po
re
),
En
gl
is
h
(S
ou
th
A
fr
ic
a)
,E
ng
lis
h
(T
ai
w
an
),
En
gl
is
h
(U
ni
te
d
St
at
es
),
Es
to
ni
an
,
Fi
nn
is
h,
Fr
en
ch
(B
el
gi
um
),
Fr
en
ch
(C
an
ad
a)
,F
re
nc
h
(S
ta
nd
ar
d)
,F
re
nc
h
(S
w
itz
er
la
nd
),
G
er
m
an
(A
us
tr
ia
),
G
er
m
an
(S
ta
nd
ar
d)
,G
er
m
an
(S
w
itz
er
la
nd
),
G
re
ek
,H
eb
re
w
,H
un
ga
ri
an
,I
ce
la
nd
ic
,I
nd
ia
(B
en
ga
li)
,I
nd
ia
(E
ng
lis
h)
,I
nd
ia
(G
uj
ar
at
i),
In
di
a
(H
in
di
),
In
di
a
(K
an
na
da
),
In
di
a
(M
al
ay
al
am
),
In
di
a
(M
ar
at
hi
),
In
di
a
(P
un
ja
bi
),
In
di
a
(T
am
il)
,I
nd
ia
(T
el
ug
u)
,I
nd
ia
(U
rd
u)
,I
nd
on
es
ia
n,
It
al
ia
n
(S
ta
nd
ar
d)
,I
ta
lia
n
(S
w
itz
er
la
nd
),
Ja
pa
ne
se
,K
or
ea
n,
La
tv
ia
n,
Li
th
ua
ni
an
,M
al
ay
,M
al
ay
(M
al
ay
si
a)
,M
al
te
se
,N
or
w
eg
ia
n,
Ph
ili
pp
in
es
(C
eb
ua
no
),
Ph
ili
pp
in
es
(T
ag
al
og
),
Po
lis
h,
Po
rt
ug
ue
se
(B
ra
zi
l),
Po
rt
ug
ue
se
(P
or
tu
ga
l),
R
om
an
ia
n,
R
us
si
an
,S
er
bi
a
(S
er
bi
an
),
Si
ng
ap
or
e
(M
al
ay
si
a)
,S
lo
va
k,
Sl
ov
en
ia
n,
So
ut
h
A
fr
ic
a
(h
os
a)
,S
ou
th
A
fr
ic
a
(Z
ul
u)
,S
pa
ni
sh
(A
rg
en
tin
a)
,S
pa
ni
sh
(C
hi
le
),
Sp
an
is
h
(C
ol
om
bi
a)
,S
pa
ni
sh
(C
os
ta
R
ic
a)
,S
pa
ni
sh
(G
ua
te
m
al
a)
,S
pa
ni
sh
(H
on
du
ra
s)
,S
pa
ni
sh
(M
ex
ic
o)
,S
pa
ni
sh
(P
er
u)
,S
pa
ni
sh
(P
ue
rt
o
R
ic
o)
,S
pa
ni
sh
(S
pa
in
),
Sp
an
is
h
(U
ni
te
d
St
at
es
),
Sp
an
is
h
(U
ru
gu
ay
),
Sp
an
is
h
(V
en
ez
ue
la
),
Sw
ed
is
h,
T
ha
i,T
ur
ki
sh
,U
kr
ai
ni
an
,V
ie
tn
am
es
e.
† G
er
m
an
,E
ng
lis
h,
Fr
en
ch
,S
pa
ni
sh
,I
ta
lia
n,
D
ut
ch
,G
re
ek
,T
ur
ki
sh
,N
or
w
eg
ia
n,
Sw
ed
is
h,
Po
lis
h,
Po
rt
ug
ue
se
,T
ai
w
an
es
e,
R
us
si
an
,S
er
bi
an
,S
er
bo
-C
ro
at
ia
n,
V
ie
tn
am
es
e,
Ja
pa
ne
se
,
A
ra
bi
an
.
‡ C
hi
ne
se
Tr
ad
iti
on
al
(H
on
g
K
on
g)
,D
an
is
h,
D
ut
ch
(B
el
gi
um
),
D
ut
ch
(N
et
he
rl
an
ds
),
En
gl
is
h
(A
us
tr
al
ia
),
En
gl
is
h
(C
an
ad
a)
,E
ng
lis
h
(U
K
-E
ir
e)
,E
ng
lis
h
(U
S)
,F
re
nc
h
(C
an
ad
a)
,F
re
nc
h
(E
ur
op
ea
n)
,G
er
m
an
(A
us
tr
ia
),
G
er
m
an
(G
er
m
an
y)
,G
re
ek
H
eb
re
w
(Is
ra
el
),
It
al
ia
n,
N
or
w
eg
ia
n,
Po
lis
h,
Po
rt
ug
ue
se
(B
ra
zi
l),
Sl
ov
ak
ia
n,
Sp
an
is
h
(C
os
ta
R
ic
a)
,S
pa
ni
sh
(Ib
er
ia
n)
,S
pa
ni
sh
(M
ex
ic
o)
,S
pa
ni
sh
(P
ue
rt
o
R
ic
o)
,S
pa
ni
sh
(U
.S
.),
Sw
ed
is
h.
§ E
ng
lis
h,
Fr
en
ch
,R
us
si
an
,T
ur
ki
sh
.
|| S
pa
ni
sh
fo
rA
rg
en
tin
a,
En
gl
is
h
fo
rA
us
tr
al
ia
,B
el
gi
um
D
ut
ch
,B
el
gi
um
Fr
en
ch
,P
or
tu
gu
es
e
fo
r
Br
az
il,
Fr
en
ch
fo
r
C
an
ad
a,
Sp
an
is
h
fo
r
C
hi
le
,C
ro
at
ia
n,
C
ze
ch
,D
an
is
h,
Fr
en
ch
,F
in
ni
sh
,G
er
m
an
,H
un
ga
ri
an
,I
ce
la
nd
ic
fo
r
Ic
el
an
d,
A
ra
bi
c,
H
eb
re
w
,R
us
si
an
,I
ta
lia
n,
Sp
an
is
h
fo
r
M
ex
ic
o,
N
or
w
eg
ia
n,
U
rd
u
fo
r
Pa
ki
st
an
,A
ra
bi
c,
Sp
an
is
h
fo
r
Pe
ru
,P
ol
is
h,
Po
rt
ug
ue
se
,R
om
an
ia
n,
R
us
si
an
,S
lo
va
ki
an
,S
lo
ve
ni
an
,S
pa
ni
sh
,S
w
ed
is
h,
D
ut
ch
,E
ng
lis
h
fo
r
th
e
U
K
,E
ng
lis
h
fo
r
th
e
U
SA
.
¶ G
er
m
an
,G
er
m
an
(A
us
tr
ia
),
C
ze
ch
,F
re
nc
h,
G
re
ek
,H
un
ga
ri
an
,E
ng
lis
h
(Ir
el
an
d)
,D
ut
ch
(N
et
he
rl
an
ds
),
Po
lis
h,
Sp
an
is
h,
Sw
ed
is
h,
G
er
m
an
(S
w
itz
er
la
nd
),
En
gl
is
h
(U
K
).
#
G
er
m
an
,E
ng
lis
h,
D
ut
ch
,F
re
nc
h,
G
re
ek
,S
w
ed
is
h.
a
=
in
te
rn
al
co
ns
is
te
nc
y;
A
IM
S2
,a
rt
hr
iti
s
im
pa
ct
m
ea
su
re
m
en
t
sc
al
es
;C
,c
hi
ld
re
po
rt
;C
H
Q
,c
hi
ld
he
al
th
qu
es
tio
nn
ai
re
;I
C
C
=
co
nc
or
da
nc
e
(in
tr
ac
la
ss
co
rr
el
at
io
n)
;P
,p
ar
en
t
re
po
rt
;N
H
P,
N
ot
tin
gh
am
he
al
th
pr
oﬁ
le
;P
ed
sQ
l,
pe
di
at
ri
c
qu
al
ity
of
lif
e
in
ve
nt
or
y;
r=
te
st
–r
et
es
t
co
rr
el
at
io
n;
SI
P,
si
ck
ne
ss
im
pa
ct
pr
oﬁ
le
,T
A
C
Q
O
L,
T
N
O
A
Z
L
ch
ild
qu
al
ity
of
lif
e;
W
H
O
Q
oL
,W
or
ld
H
ea
lth
O
rg
an
iz
at
io
n
qu
al
ity
of
lif
e;
W
O
M
A
C
,W
es
te
rn
O
nt
ar
io
an
d
M
cM
as
te
r
U
ni
ve
rs
iti
es
os
te
oa
rt
hr
iti
s
in
de
x.
PROs and Hemophilia 811
instruments for generic quality of life assessment in children.
Very recently, the European KIDSCREEN instrument has been
simultaneously developed in several languages and validated in
over 20,000 children, but has not yet been applied in pediatric
hemophilia research. The same is true for a new chronic generic
measure: the DISABKIDS instrument. The DISABKIDS instru-
ment focuses on the experience of having a chronic illness and
originated, as did the KIDSCREEN, from a European research
consortium [55,56]. Both instruments are age-group related,
were derived from respondents’ focus groups, and can be com-
pleted by children/adolescents from the age of 8 years and by
parents. For the DISABKIDS, a smiley version for younger chil-
dren (4–7 years) has been developed. Especially, the newer instru-
ments provide assessments of core HRQoL concepts as well as
modules for different diseases are brief and are psychometrically
well tested. All of these instruments sufﬁciently fulﬁll psychomet-
ric criteria of reliability and validity and are available in various
languages (see Table 1b). The PedsQL has so far been included in
the hemophilia published literature [57], as have the KINDL
Questionnaire [58] and the CHQ [59,69].
Targeted Quality of Life Measures for Children
and Adults
Hemophilia-speciﬁc HRQoL measures for adults. In addition to
generic scales, which had been used before, hemophilia-speciﬁc
HRQoL measures for adults have only very recently been pub-
lished according to the guidelines of international instrument
construction. The HAEMO-QOL-A questionnaire was devel-
oped internationally [60]; initially, focus groups were conducted
simultaneously in participating countries to derive items. The
HAEMO-QOL-A consists of 41 items representing six relevant
HRQoL dimensions: physical functioning, psychosocial issues,
role functioning, fear/worry, positive affect, and treatment worry,
and is available in several languages. Psychometric characteristics
showed good values for reliability and satisfactory values for
validity (concurrent, discriminant). The questionnaire was pilot-
tested in the United States, translated, and was ﬁeld-tested in the
United States, Spain, and Germany, in 221 patients. The Haem-
A-QoL [61] instrument was compiled from focus groups of
patients with hemophilia in Italy who were interviewed about
their perceptions of their condition and treatment. The Haem-
A-QoL consists of 46 items pertaining to 10 dimensions with an
average completion time of 14 minutes. The Haem-A-QoL has a
core instrument consisting of 27 items that are identical to items
in the pediatric Haemo-QoL questionnaire (see further discus-
sion), and thus allows a comparison between children’s and
adults’ hemophilia-speciﬁc quality of life and the ability to assess
patients’ HRQoL from early childhood to adulthood [62]. The
Haem-A-QoL was validated in the Italian Cost of Care of Hemo-
philia Study (COCHE) in 233 Italian adult patients with hemo-
philia. The psychometric characteristics include good reliability
(ranging from a = 0.74–0.88), and high convergent (correlation
with SF-36) and discriminant validity (e.g., severity and infec-
tions) [63]. The Haem-A-QoL has been translated into 21 lan-
guages using a quality-controlled forward/backward translation
procedure; cross-cultural validity was determined with positive
results by clinicians’ reviews in 17 languages [64].
The Hemoﬁlia-QoL [65] was developed in Spain and consists
of 36 items reﬂecting to nine scales: physical health (eight items),
daily activities (four items), joint damage (three items), pain (two
items), treatment satisfaction (two items), treatment difﬁculties
(four items), emotional functioning (ﬁve items), mental health
(three items), and relationship and social activities (ﬁve items).
Psychometric testing demonstrated acceptable reliability values
with Cronbach’s a = 0.95 for the Hemoﬁlia-QoL total score and
adequate convergent validity with the SF-36 subscales. The ques-
tionnaire was ﬁeld-tested in 121 hemophilic patients in Spain.
Also, the Hemolatin-QoL Questionnaire [66] from Latin
America is a newer instrument available in Spanish as well as
Portuguese for Brazil with current psychometric testing under-
way. A newer French instrument, the hemophilia age-group spe-
ciﬁc quality of life questionnaire assessing 11 domains with 89
items, is currently under validation [67].
The instruments reviewed are all designed to evaluate efﬁcacy
of treatment, assess symptoms/signs, functional status, and
health perception, and include multiple items from multiple
domains in multiple concepts. They are self-administered, all
spanning a 4-week time frame, and yielding proﬁle and compos-
ite scores. Patients are asked to ﬁll out the questionnaires that can
be administered in person or by mail. Face-to-face and phone
surveys are possible, but have not been conducted so far. An
article comparing the concepts of three adult measures (Haemo-
QoL-A, Haem-A-QoL, Hemoﬁlia-QoL) found that they all
address ﬁve concepts of HRQoL in hemophilia, with, however,
different items, namely physical, emotional, social, functional,
mental, and treatment-related dimensions [63] (Table 2).
Hemophilia-speciﬁc HRQoL measures for children. A special
problem with measuring HRQoL among children is the age
dependence of quality of life domains as well as difﬁculties
obtaining their self-report throughout the developmental stages.
Two of the ﬁrst measures for children with hemophilia were
developed concurrently: the Haemo-QoL [68,69] and the
Canadian Haemophilia Outcomes–Kids Life Assessment Tool
(CHO-KLAT) [70]. Both are able to capture the perspectives
of children’s and parents’ in separate versions.
The initial development of the Haemo-QoL questionnaire
used parents’ assessment of children’s quality of life as well as
clinical expert consensus on relevant dimensions. This input was
used to construct a quality of life instrument for children. State-
ments were then modiﬁed for three age groups (4–7, 8–12,
13–16 years) of children and tested for acceptance using cogni-
tive debrieﬁng techniques. The age-speciﬁc versions differ in
number of domains and items, but contain an identical core item
set. The Haemo-QoL was pilot-tested in 58 children and their
parents and ﬁeld-tested and validated in 339 children and their
parents in six European countries (Germany, Italy, Spain, France,
the UK, and The Netherlands) [58]. These validated Haemo-QoL
versions can be downloaded from the Haemo-QoL website
(http://www.haemoqol.de). Moreover, the Haemo-QoL has been
linguistically cross-cultural validated in 30 languages.
Psychometric analysis revealed good psychometric properties
both for the interview-based form in small children (21 items),
the self-report in children age 8–12 (64 items), and adolescents
13–16 years (77 items) as well as for the corresponding forms for
parents. Cronbach’s alpha for the total score varied from
a = 0.85 to 0.91. The convergent validity of the questionnaire
was satisfactory.
In addition to the full version, a short version for small
children (4–7 years) containing 16 items and a short version for
older children (8–16 years) containing 35 items were developed
and showed excellent psychometric properties. An eight-item
index version was developed spanning all age groups, which is
also available as a self- and parent-report (Haemo-QoL-Index)
[71].
The CHO-KLAT was developed initially in Canada and a
single cross-age version was sought [70]. The CHO-KLAT is
unique in being developed primarily from ﬁrst principals and from
812 Bullinger et al.
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the perspectives of children with hemophilia of all ages. Priority at
all stages of the development of the CHO-KLAT was given to
children to ensure that the measure reﬂected the perspectives of
children and could be used by self-report by children. The CHO-
KLAT is available for children 4 to 18 years of age and includes
parents- and self-report forms [70]. The CHO-KLAT consists of
35 items and has a single summary score representing overall
quality of life based on questions regarding treatment, physical
health, family, future, feeling, understanding of hemophilia, other
people and friends, and control over your life. Child–parent
concordance is very strong (intraclass correlation coefﬁcient
[ICC] = 0.75), as is consistency over time for both child self-report
(ICC = 0.74) and parent proxy report (ICC = 0.83).
The instrument was pilot-tested in a group of 52 children and
is currently ﬁeld-tested in a larger group. The CHO-KLAT is
available in English (both Canadian and UK versions), French
(both Canadian and France versions), Spanish, Dutch, and
German. Furthermore, the CHO-KLAT and Haemo-QoL have
been used conjointly in a recent retrospective analysis that
showed acceptable psychometric properties as well as strengths
and weaknesses of both measures [72].
The instruments reviewed so far evaluated efﬁcacy and
assessed symptoms and signs, as well as functional status for
multiple domains with multiple concepts. All measures are self-
reported, relate to the past 4 weeks and are ﬁlled out by the
children. In young children from the early age of 4 years onward,
they are interview administered. Each of the measures is also
available for parent-proxy report using the same items formu-
lated from the parents’ perspective.
Other targeted instruments for children with hemophilia have
also been published. For example, Manco-Johnson et al. [73]
developed and tested a parent-administered instrument to assess
the HRQoL of very young children between 2 and 6 years. Some
of the other more recent measures in young hemophilia patients
such as the Dutch Hem-Dux [74], however, still have to undergo
more extended psychometric testing.
Preference Measures
Generic PPM for Adults and Children
Within the indirect assessment approach, systematic generic
patient-preference measurement has begun as early as 1980—
and has since then been used in health economic studies of
chronic diseases. Older measures such as the QWB [75] were
complemented by newer approaches such as EUROQOL [76],
now named EQ-5D [77], Health Utilities Index (HUI) [78], and
the SF-6D [17].
The EQ-5D is a generic, utility-based instrument assessing ﬁve
dimensions: mobility, self-care, usual activities, pain, and anxiety/
depression [79]. The utility score from this measure is derived
from community-based preference scores assigned to several
health scenarios, created by the permutation and combination of
the degrees of capacity or impairment across the ﬁve different
health dimensions. The EQ-5D was psychometrically tested for
reliability [80] and validity [81,82]. Recently, a patient-preference
version of the SF-36, the SF-6D, has been developed, which can be
administered directly or can be derived from the SF-36 items [83].
Validity information on the SF-6D, compared with the EQ-5D,
has been reported by Petrou et al. [84]. In addition, the HUI
[85,86] has been utilized with adults and is the only generic PPM
instrument so far used with children. Reliability [87] and validity
[88] have been reported for the general adult population.
Multiattribute health states assessed in the HUI Mark 3
include vision, hearing, speech, ambulation, dexterity, emotion,
cognition, and pain. In hemophilia, these measures have been
included only very recently.
In an effort to begin to assess PPMs in adult patients with
hemophilia A and B, Miners et al. [89] utilized both the SF-36
and the EQ-5D. The authors found that individuals with severe
hemophilia have reduced levels of HRQoL compared with: 1)
individuals with moderate or mild forms of the disease; and 2)
with the UK male normative population.
Targeted PPM for Adults and Children
Newer developments have included efforts to derive disease-
speciﬁc utilities, oriented at the target health issues associated
with a given disease. As one of the ﬁrst approaches in the use of
utility-based measures in hemophilia [90], Wasserman et al.
(2005) developed and validated a disease-speciﬁc utility instru-
ment that directly measured patient preferences for nine unique
hemophilia health states [91]. Health states ranged from mild to
severe and included common morbidities experienced by persons
with hemophilia. The VAS and the SG methods were both used to
assess preferences. The authors found statistically signiﬁcant dif-
ferences for all health states combined between pediatric and
adult participants (P = 0.045) as well as differences among adult
and pediatric group preferences for the mild, severe (episodic
treatment), and severe (prophylactic treatment) health states.
These results indicated that age can inﬂuence patients’ prefer-
ences regarding their state of health (Table 3).
Recent research demonstrated that both generic and disease-
speciﬁc instruments can be used to reliably measure utilities in
hemophilia. However, given the complex nature of the disease, its
unique characteristics, and the comorbidities often associated
with it, there is a need for multiattribute preference measure-
ments. To date, no preference measure integrating two or more
health states (multiattribute) has been developed for this popu-
lation. Reliable and valid generic (e.g., EQ-5D) and disease-
speciﬁc (e.g., TTO or algorithms of indirect methods) can be used
to integrate multiple attributes into a single preference instru-
ment for hemophilia.
Inclusion of HRQoL and PPM Measures in Hemophilia
Research and Care
Given the short history of PROs, it is not surprising that only few
studies have used HRQoL and PPM measures in hemophilia and
that no randomized clinical trials have been published yet.
Within the 210 citations identiﬁed from the literature search,
many used respective keywords without having empirically
addressed the topic. Examples of including quality of life mea-
sures are cross-sectional studies to better understand patients’
quality of life as related to hemophilia [92] in speciﬁc cultural
settings (e.g., the Chinese population) [93] in speciﬁc disease
conditions (e.g., von Willebrand Disease) [94], regarding com-
plications (HIV, inhibitors) [2] or impact of events (e.g., intrac-
ranial bleeds and arthropathy) [95,96].
Only recently, studies are underway combining quality of life
and PPM assessments [97–99]. In comparison, PPM measures
have primarily been used in health economic studies. Neverthe-
less, both measures are increasingly included in comprehensive
health outcome studies [100], such as the European Study of
Clinical, Health-Economic and Quality of Life outcomes in
hemophilia (http://www.eschqol.lmu.de). In this multinational
study, HRQoL and PPM measures are used conjointly and pro-
spectively in more than 1400 patients from 21 European coun-
tries, namely adults and children as well as their parents.
Furthermore, PPM and HRQoL concepts are also inter-
related. Patient preferences are an important factor in the
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assessment of overall HRQoL and vice versa. Patient preferences
for a particular health state can be associated with the likelihood
of seeking care, the type of treatment selected, selection of pro-
vider specialty, and compliance with care [101].
Preferences along with individual and environmental charac-
teristics shape an individual’s perception of his/her general
health. For example, high utilization of health-care services is
potentially associated with poorer self-reported health status.
Because patient preferences are related to an individual’s percep-
tion of health status, it is not surprising that results vary with
respondent characteristics. Initial investigations have supported
the existence of a relationship between health-state preferences
and patient health-seeking behavior. For instance, Fifer et al.
[102] demonstrated that prescriptions for psychotropic medica-
tions for patients with anxiety were related to patient self-
assessment of the desirability of their current state. The
association between patient preferences and treatment decisions
of patients with hemophilia has not been explored, and it is not
yet known how severity of hemophilia, treatment of hemophilia,
patient preferences, and quality of life might be related [100].
Choosing PRO Measures in Hemophilia
The selection of the HRQoL or PPM measures should be guided
by the study-related and instrument-related aspects [62].
Instrument-related characteristics include the concepts assessed,
the psychometric properties and feasibility of the instrument.
Because study objectives vary, relevant concepts will have to
reﬂect the dimensions under study. As concerns comparisons of
dimensions or domains assessed across instruments, this consti-
tutes a difﬁcult task. The reason is that although domain names
might seem similar, close inspection of their content shows a wide
variation. Beyond a classiﬁcation of very broad domains (phy-
sical, emotional, social), a speciﬁc comparison makes a close
inspection of the items included in subscales of an instrument
necessary. As concerns the study purpose, there is a wide range of
study designs and objectives including a description of the patient
population (epidemiological, cross sectional), a description of
change over time in the patient cohort (longitudinal prospective),
a comparative evaluation of treatment outcomes (randomized
clinical trials), an evaluation of the quality of care (longitudinal
quality assurance studies), or an assessment of treatment beneﬁt
(health economic studies).
Study designs for research speciﬁc to hemophilia care includ-
ing HRQoL and PPM measures may serve different purposes. For
instance, a cross-sectional or epidemiological description of
patients’ quality of life that is linked to clinical sociodemographic
or other psychosocial characteristics is important for making
funding and access decisions. If the comparison is meant to
concern hemophilia patients only, the choice of a hemophilia-
speciﬁc measure might be sufﬁcient, especially if one is interested
in subdividing patient populations according to clinical charac-
teristics. Nevertheless, if the purpose is to compare hemophilia
patients with populations suffering from other chronic condi-
tions, the use of a generic measure is a prerequisite. Studies
focusing on following patients’ HRQoL over time in terms of a
naturalistic setting or in terms of longitudinal cohort studies,
which might or might not involve an intervention, usually beneﬁt
from both types of assessments: targeted and disease-speciﬁc.
Several studies have postulated that changes can be detected
most sensitively with disease-speciﬁc measures, but other studies
have reported that such changes over time are also discernable
with generic scales. A solution is to combine generic and targeted
measures in a modular fashion. Some measures—especially the
pediatric ones—have been designed that way, for example theTa
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PEDsQL, the KINDL-R, and the DISABKIDS have a generic core
and disease-speciﬁc modules. In hemophilia literature, the head-
to-head comparison or combination of both generic and disease-
speciﬁc scales for assessment of HRQoL or PPM has yet to be
completed.
Controlled, randomized clinical trials include PRO measures
as primary or secondary end points. If the measures are to be
used as primary end points, the criteria for selecting the measure
should include previous knowledge of the measures performance
in other trials in the same population and psychometric evidence.
Prior estimates of the sample size necessary to detect changes
over time and differences between groups should be utilized.
If the clinical trial is multinational, it is important that the
measure has been translated and psychometrically tested in the
relevant cultural and linguistic contexts. In hemophilia, multina-
tional patient recruitment is frequently necessary to accumulate a
sufﬁcient number of patients in studies. Thus, it is extremely
helpful if psychometric analysis of measures have already been
performed in different countries, so that an instrument can be
used in hemophilic patients around the world.
This is, for example, the case for the recently developed
quality of life measures in hemophilia, both for children (e.g.,
Haemo-QoL for children) and for adults (e.g., Haemo-QoL-A,
Haem-A-QoL), and it is also true for a range of generic and
targeted measures.
In children, speciﬁc problems arise regarding the age from
which children can respond to a questionnaire. Usually, if appro-
priate forms of questioning and graphic reports are used, chil-
dren from an age as early as 4 years can give information on their
quality of life. Nevertheless, for PPM measures, good-level
reading and writing and a generally well-developed cognitive
functioning is expected. Another question pertains to whether
parents (as proxies) should be included. Research on correlation
between parent and child report shows, depending on the area of
quality of life assessed, high correlations (for example for the
physical function), but the emerging picture is complex and does
not easily conclude that one mode of report may be substituted
by the other.
Regarding the choice of measures, recommendations based
on the literature review and intensive discussion within the
Expert HRQoL Working Group of the IPSG expert group, are:
1. reﬂect on aim, design, patient, and scientiﬁc reasons for
HRQoL assessment
2. always seek the opinion of the patient; observers provide
valuable additional, but not identical information. Parent
ratings for very young children are acceptable
3. use methodologically sound instruments providing inter-
pretable scores
4. implement generic and targeted instruments conjointly as
both pick up intervention effects; generic scales reﬂect
HRQoL impact on the population level
5. if instrument alternatives are available, combine the short
form of one with the long form of the other, to be used for
item banking and further instrument development
6. use HRQoL and health economic instruments conjointly, if
possible
Instruments can be used to derive utilities (SF-6D, EQ-5D,
HUI, QWB), but so far, little is known about their responsiveness
in hemophilia. Themost important overall recommendation (was)
is to include PRO instruments and to examine their properties in
future studies. The reason for this general recommendation is the
paucity of empirical results regarding the use of measures in
clinical studies and trials so far. As has been demonstrated, generic
and targeted measures for adults and children to assess PROs in
terms of HRQoL and patient preferences are available. Neverthe-
less, they have not yet been sufﬁciently included in hemophilia
studies, so that conﬁrmation of psychometric properties in a
speciﬁc study context, especially regarding speciﬁcity and respon-
siveness, is still lacking. Only the proactive and timely inclusion of
these measures will aid solving urgent problems in prophylactic
research over the patient’s life span, such as when to start, when to
stop, and when to modify the course of treatment recognizing its
impact on patients’ lives [103].
Discussion
In the area of PROs, generic and disease-speciﬁc instruments are
available to assess HRQoL and patient preferences in adults and
in children with hemophilia. These instruments were recently
developed from patient input and can be therefore expected to
assess relevant HRQoL domains in hemophilia. The studies were
designed to psychometrically test these measures before they can
be used in clinical studies. Such use will help determine which
generic/disease-speciﬁc instrument is more sensitive to measure
PROs in hemophilia across severity and over time to evaluate
change. The majority of these measures were developed before
the dissemination of the FDA PRO draft guidance. The most
recently developed instrument (Haemo-QoL, CHO-KLAT, and
Haem-A-QoL) have incorporated a patient-centric approach
along with rigorous psychometric analyses throughout the devel-
opment process, consistent with the FDA guidance. Comparison
of the existing measures (such as the SF-36) with the FDA guid-
ance has been completed by other investigators and is beyond the
scope of this article. The current article sets out to present mea-
sures that can be used in a wide range of studies from clinical
trials to observational studies, and is not speciﬁcally focused on
integrating PRO impact into labels approved by regulatory agen-
cies such as the European Medicines Agency (EMEA) or FDA.
Choosing between instruments can pose challenges to the
individual researcher or clinician. The existence of different PRO
instruments and their scarce use in research and clinical settings
makes it difﬁcult to obtain enough empirical data about speciﬁc
instruments’ performance, thereby preventing comparisons.
Nevertheless, the availability of alternative measures is often
necessary to determine those approaches that are conceptually
appropriate, methodologically sound, and practically applicable.
For example, a recent publication addresses the comparison of
disease-speciﬁc measures HRQoL for children with hemophilia
[72]. One of these measures, the CHO-KLAT, was developed in
Canada with emphasis on the perspectives of children. Another,
the Haemo-QoL, was developed in Europe, with emphasis on the
perspectives of clinicians. Although these two measures are
unique and independent, researchers from both studies were
collaboratively linked throughout development and testing. The
strengths, limitations, and unique contributions of these two
measures have been compared using a retrospective analysis of
data from ﬁeld-testing of both measures [72]. The analysis
included a comparative assessment of the basic validity, reliabil-
ity, and items used in each measure. Overall, the results showed
that the CHO-KLAT and the Haemo-QoL are promising and
valuable measures of HRQoL for children with hemophilia.
Analyses conﬁrmed the basic psychometric properties of both
tools, but identiﬁed some discrepancies between them. Addi-
tional data is expected to allow for greater understanding of
these discrepancies and lend clarity as to how the tools should be
used in clinical studies (separately or merged). The present rec-
ommendation is that the measures be run independently, but
preferably concurrently in studies of children with hemophilia.
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Combination of measures (i.e., a generic with a disease-
speciﬁc HRQoL measure) might be helpful for researchers and
clinicians, but patient burden has to be considered. To minimize
respondent burden, one strategy to achieve optimal information
on measurement performance would be to use core sets of instru-
ments across studies. The development of short forms, which
reﬂects the need to assess quality of life or patient preference
concisely and parsimoniously, may help in this development.
Clearly, it is beneﬁcial to use common strategies for quality of life
assessment in a rare disease such as hemophilia. Patient prefer-
ences enable investigators to quantify the level of impairment of
an individual due to a speciﬁc disease state. The degree to which
a patient values the improvement in HRQoL from a given treat-
ment can also be assessed through preference (utility) scores.
Utility measures have been integrated into outcomes and eco-
nomic analysis across a myriad of clinical conditions including
coronary artery disease, depression, and asthma [4,104]. Infor-
mation concerning the relative costs of alternative interventions
and their impact on outcomes of value to the patient are impor-
tant for accurate estimates from these analyses. The evaluation of
treatment approaches such as prophylaxis is a potential applica-
tion of utility measurement in hemophilia.
Frequently, patient preference and quality of life measures are
used independently. However, research, such as economic analy-
ses, can be enriched by incorporating both methods. One possi-
bility is to use the HRQoL instruments in health economic
research. The second possibility is to use quality of life measures
that in themselves make it possible to derive utility values. These
include the SF-6D, derived from the SF-36 Health survey, as
well as the EQ-5D. A third possibility is to further develop
hemophilia-speciﬁc patient preference methodology. Wasserman
et al. [91] developed an instrument to measure patient preferences
for speciﬁc hemophilia health states. For clinical practice, the
combination of both methods is critical because reimbursement
policies are often based on both economic and quality of life data.
PPMs are a useful way to translate the beneﬁts of prophylac-
tic care into economic terms. This information is imperative to
justify the high up front costs of prophylactic care from the
perspective of the hemophilic patient. To date, completion of
economic models has been difﬁcult because of two issues. First,
few studies have integrated a PPM, so utilities for various hemo-
philia health states at different periods of time are scarce.
Research, such as that conducted by Wasserman et al. [91], as
well as general measures used in current prospective studies in
both the United States and Europe, will help to ﬁll this gap.
Second, although some cost studies have been conducted in the
past decade, the detailed information needed to include the
models is also limited. Recent developments in economic model-
ing techniques, as well as cost studies in the United States (e.g.,
Haemophilia Utilization Study Group [HUGS] V) [105,106] and
in Europe (COCIS is the Italian version of cost of Care in Hae-
mophilia [and COCHE]) [2,107], will provide the breadth of
detail needed for these models. Measuring HRQoL in hemophilia
clinical research will provide important data to integrate the
beneﬁt of economic treatment to the patient into economic analy-
ses that are needed to justify reimbursement for prophylactic care
throughout the world.
As repeatedly stated by proponents of evidence-based medi-
cine, treatment choices should be based as much as possible on
an empirical foundation, obtained via high-quality studies, focus-
ing on results of well-designed prospective clinical trials and the
meta-analysis or pooling of data. Informed decision-making,
however, is only possible if such data exist, and in persons with
hemophilia for quality of life as well as patient preference, this is
not yet the case. Speciﬁc treatment scenarios such as implanting
a port-a-cath in young children, identifying the best prophylaxis
strategy, and changing treatment strategies in later life, are
examples of hemophilia care delivery that would greatly beneﬁt
from quality of life and patient preference evaluation. These
measures should be incorporated as much as possible into
research to augment the data upon which to base the best choice
of treatment strategies for patients with hemophilia. It is thus
hoped that the use of PROs will lead to a better understanding of
the beneﬁts and limitations of prophylaxis strategies in persons
with hemophilia, and would ultimately aid in clinicians and
policymakers in delivering appropriate care to hemophilic
patients by assessing the outcomes of treatment.
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